COMMUNIQUÉS West-GlobeNewswire

Algernon Pharmaceuticals Completes Name Change to Algernon Health
15/10/2025
VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has [...]
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
15/10/2025
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by [...]
Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases
15/10/2025
• TRB-ILD1 granted U.S. Orphan Drug Designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF) • TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment of glioblastoma (GBM) [...]
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
15/10/2025
ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
15/10/2025
AMX-883 uses Amphista’s Targeted Glue™ technology, inducing degradation of BRD9 through the recruitment of DCAF16, a completely distinct mechanism of action from cereblon- or VHL-based PROTACs. The nomination of AMX-883 [...]
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
15/10/2025
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., Oct. 15, 2025 ( [...]
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
15/10/2025
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading [...]
Communiqué de presse : Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes
15/10/2025
Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes Montpellier, 15 octobre 2025. Sanofi a lancé aujourd'hui à Montpellier un Centre d'Excellence Translationnel, en [...]
MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29
15/10/2025
MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended [...]
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
15/10/2025
SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis will promptly wind-down and terminate the MARIO study The payment [...]
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
15/10/2025
WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Beacon Therapeutics to Participate in Chardan’s 9th Annual Genetic Medicines Conference
15/10/2025
LONDON and CAMBRIDGE, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and [...]
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
15/10/2025
ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation study Further ATRN-119 monotherapy enrollment paused with strategic focus on high-value combination Company is [...]
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
15/10/2025
A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells PARIS, Oct. 15, 2025 ( [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
15/10/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 15 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
15/10/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE [...]
Vara earns CE mark as the only AI authorized for an independent second read in mammography, and expands in Europe
15/10/2025
BERLIN, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Vara announced today it received a new CE certificate for its new breast-imaging AI – the only on the market allowed to operate as an independent second reader for both [...]
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
15/10/2025
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patients Real-world evidence and long-term data reinforce VYVGART’s sustained impact on patient [...]
EyePoint Announces Pricing of Public Offering
15/10/2025
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]

Pages